Progress in Gene Therapy for Prostate Cancer

Gene therapy has held promise to correct various disease processes. Prostate cancer represents the second leading cause of cancer death in American men. A number of clinical trials involving gene therapy for the treatment of prostate cancer have been reported. The ability to efficiently transduce tu...

Full description

Bibliographic Details
Main Authors:	Ahmed, Kamran A., Davis, Brian J., Wilson, Torrence M., Wiseman, Gregory A., Federspiel, Mark J., Morris, John C.
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500761/

id	pubmed-3500761
recordtype	oai_dc
spelling	pubmed-35007612012-11-23 Progress in Gene Therapy for Prostate Cancer Ahmed, Kamran A. Davis, Brian J. Wilson, Torrence M. Wiseman, Gregory A. Federspiel, Mark J. Morris, John C. Oncology Gene therapy has held promise to correct various disease processes. Prostate cancer represents the second leading cause of cancer death in American men. A number of clinical trials involving gene therapy for the treatment of prostate cancer have been reported. The ability to efficiently transduce tumors with effective levels of therapeutic genes has been identified as a fundamental barrier to effective cancer gene therapy. The approach utilizing gene therapy in prostate cancer patients at our institution attempts to address this deficiency. The sodium-iodide symporter (NIS) is responsible for the ability of the thyroid gland to transport and concentrate iodide. The characteristics of the NIS gene suggest that it could represent an ideal therapeutic gene for cancer therapy. Published results from Mayo Clinic researchers have indicated several important successes with the use of the NIS gene and prostate gene therapy. Studies have demonstrated that transfer of the human NIS gene into prostate cancer using adenovirus vectors in vitro and in vivo results in efficient uptake of radioactive iodine and significant tumor growth delay with prolongation of survival. Preclinical successes have culminated in the opening of a phase I trial for patients with advanced prostate disease which is currently accruing patients. Further study will reveal the clinical promise of NIS gene therapy in the treatment of prostate as well as other malignancies. Frontiers Media S.A. 2012-11-19 /pmc/articles/PMC3500761/ /pubmed/23181221 http://dx.doi.org/10.3389/fonc.2012.00172 Text en Copyright © 2012 Ahmed, Davis, Wilson, Wiseman, Federspiel and Morris. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Ahmed, Kamran A. Davis, Brian J. Wilson, Torrence M. Wiseman, Gregory A. Federspiel, Mark J. Morris, John C.
spellingShingle	Ahmed, Kamran A. Davis, Brian J. Wilson, Torrence M. Wiseman, Gregory A. Federspiel, Mark J. Morris, John C. Progress in Gene Therapy for Prostate Cancer
author_facet	Ahmed, Kamran A. Davis, Brian J. Wilson, Torrence M. Wiseman, Gregory A. Federspiel, Mark J. Morris, John C.
author_sort	Ahmed, Kamran A.
title	Progress in Gene Therapy for Prostate Cancer
title_short	Progress in Gene Therapy for Prostate Cancer
title_full	Progress in Gene Therapy for Prostate Cancer
title_fullStr	Progress in Gene Therapy for Prostate Cancer
title_full_unstemmed	Progress in Gene Therapy for Prostate Cancer
title_sort	progress in gene therapy for prostate cancer
description	Gene therapy has held promise to correct various disease processes. Prostate cancer represents the second leading cause of cancer death in American men. A number of clinical trials involving gene therapy for the treatment of prostate cancer have been reported. The ability to efficiently transduce tumors with effective levels of therapeutic genes has been identified as a fundamental barrier to effective cancer gene therapy. The approach utilizing gene therapy in prostate cancer patients at our institution attempts to address this deficiency. The sodium-iodide symporter (NIS) is responsible for the ability of the thyroid gland to transport and concentrate iodide. The characteristics of the NIS gene suggest that it could represent an ideal therapeutic gene for cancer therapy. Published results from Mayo Clinic researchers have indicated several important successes with the use of the NIS gene and prostate gene therapy. Studies have demonstrated that transfer of the human NIS gene into prostate cancer using adenovirus vectors in vitro and in vivo results in efficient uptake of radioactive iodine and significant tumor growth delay with prolongation of survival. Preclinical successes have culminated in the opening of a phase I trial for patients with advanced prostate disease which is currently accruing patients. Further study will reveal the clinical promise of NIS gene therapy in the treatment of prostate as well as other malignancies.
publisher	Frontiers Media S.A.
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500761/
_version_	1611925015810277376

Progress in Gene Therapy for Prostate Cancer

Similar Items